Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
Active, not recruiting · Not applicable · NCT05478304
Conditions: Ischemic Stroke, Systemic Embolism
At a glance
- Research payments reported, 2025
- $3,565
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 6,573
About the trial
- Sponsor
- AtriCure, Inc. (with Population Health Research Institute)
- Tested
- AtriClip LAA Exclusion System (device)
- Dates
- Started 2023-01-25; completion 2032-04
- Results posted
- Not yet
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Atricure, Inc. reported $3,565 in research payments for this study in 2025 (2 payments).
Products named: Atriclip Laa Exclusion System
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sutter Sacramento $3,565
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.